Loading...
Mira is a 34-year-old software engineer who just completed her annual health screening at MedTech Labs. Three days later, her doctor calls with unsettling news: she tested positive for Harmon's Syndrome, a rare autoimmune condition. The test, her doctor explains, is 99% accurate — it correctly identifies 99% of people who have the disease, and correctly clears 99% of people who don't. Mira spirals. She cancels a vacation, tells her sister, and starts researching treatment options. The number '99% accurate' echoes in her mind. How could she be in the unlucky 1%? But here's what Mira doesn't consider: Harmon's Syndrome affects just 1 in 10,000 people. Her doctor ordered the test as part of a routine panel, not because of symptoms. Imagine testing all 10,000 people in Mira's town. On avera...
Popular framing: A 99%-accurate test said positive, so Mira probably has the disease.
Structural analysis: When a rare condition is screened in an unselected population, the base rate dominates the test characteristics — Bayes' theorem makes false positives outnumber true positives even at 99% accuracy because the prior is 1 in 10,000. The doctor anchored on the test's sensitivity rather than the post-test probability and skipped the base-rate calculation entirely. The same test on the same patient with the same result produces the same misleading positive regardless of who reads it; the failure is in the screening protocol, not in any individual's judgement.
The gap matters because it causes systematic, predictable harm: unnecessary psychological distress, financial cost, and downstream medical interventions for patients who are overwhelmingly healthy. It also undermines trust in medicine when the 'error' is eventually revealed. Closing the gap requires not individual Bayesian literacy but redesigned result communication that embeds prior probability into every positive result disclosure.
